These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Matsuo O; Rijken DC; Collen D Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339 [TBL] [Abstract][Full Text] [Related]
26. Local intravenous thrombolysis with recombinant tissue plasminogen activator for salvage of forearm replantation. Hashim HA; Atiyeh BS; Hamdan AM; Musharrafieh RS J Reconstr Microsurg; 1996 Nov; 12(8):543-6. PubMed ID: 8951123 [TBL] [Abstract][Full Text] [Related]
27. [Fibrinolysis and thrombolysis after administration of tissue plasminogen activator in dogs]. Malinovskiĭ NN; Andreenko GV; Maksimovich IV; Shimonaeva EE; Liutova LV Vestn Akad Med Nauk SSSR; 1985; (7):52-8. PubMed ID: 4050079 [No Abstract] [Full Text] [Related]
28. Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture. Bykowska K; Rijken DC; Collen D Thromb Haemost; 1981 Oct; 46(3):642-4. PubMed ID: 7198301 [TBL] [Abstract][Full Text] [Related]
29. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448 [TBL] [Abstract][Full Text] [Related]
31. [Development of research into the physiology and pathophysiology of the fibrinolysis system]. Andreenko GV Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (10):5-19. PubMed ID: 2933082 [TBL] [Abstract][Full Text] [Related]
32. [Structure, function and use of fibrinolysis-promoting and inhibiting factors]. Bachmann F Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901 [TBL] [Abstract][Full Text] [Related]
33. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Heeremans JL; Prevost R; Bekkers ME; Los P; Emeis JJ; Kluft C; Crommelin DJ Thromb Haemost; 1995 Mar; 73(3):488-94. PubMed ID: 7667833 [TBL] [Abstract][Full Text] [Related]
35. [Laboratory control of fibrinolytic therapy]. Vinazzer H Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):30-7. PubMed ID: 2427412 [TBL] [Abstract][Full Text] [Related]
36. Design and characterization of a platelet-targeted plasminogen activator with enhanced thrombolytic and antithrombotic potency. Yan HL; Sun SH; Wang WT; Ding FX; Mei Q; Xue G Biotechnol Appl Biochem; 2007 Feb; 46(Pt 2):115-25. PubMed ID: 16965265 [TBL] [Abstract][Full Text] [Related]
37. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids. Thorsen S Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205 [No Abstract] [Full Text] [Related]
38. [New thrombolytic drugs]. Kopeć M Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):127-30. PubMed ID: 2216951 [No Abstract] [Full Text] [Related]
39. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy]. Veremeenko KN; Kizim AI Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892 [TBL] [Abstract][Full Text] [Related]
40. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]